MA51295A - Dosage, procédé et traitement d'alpha-synucléinopathies - Google Patents

Dosage, procédé et traitement d'alpha-synucléinopathies

Info

Publication number
MA51295A
MA51295A MA051295A MA51295A MA51295A MA 51295 A MA51295 A MA 51295A MA 051295 A MA051295 A MA 051295A MA 51295 A MA51295 A MA 51295A MA 51295 A MA51295 A MA 51295A
Authority
MA
Morocco
Prior art keywords
synucleinopathies
dosage
alpha
treatment
Prior art date
Application number
MA051295A
Other languages
English (en)
Inventor
Karina Fog
Pekka Kallunki
Ibrahim John Malik
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA51295A publication Critical patent/MA51295A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
MA051295A 2017-12-21 2018-12-19 Dosage, procédé et traitement d'alpha-synucléinopathies MA51295A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201700738 2017-12-21

Publications (1)

Publication Number Publication Date
MA51295A true MA51295A (fr) 2021-05-05

Family

ID=65011965

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051295A MA51295A (fr) 2017-12-21 2018-12-19 Dosage, procédé et traitement d'alpha-synucléinopathies

Country Status (7)

Country Link
US (1) US20200309796A1 (fr)
EP (1) EP3729088B1 (fr)
JP (2) JP7498663B2 (fr)
CN (2) CN120195406A (fr)
ES (1) ES2898929T3 (fr)
MA (1) MA51295A (fr)
WO (1) WO2019121952A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019114679A (ru) 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
EP3555127B1 (fr) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, utilisations et procédés
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
CN115032400A (zh) * 2022-03-28 2022-09-09 首都医科大学附属北京天坛医院 α-突触核蛋白在辅助诊断神经退行性疾病中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1186621A (fr) 1981-08-10 1985-05-07 John L. Hendrix Systeme de dosage immunologique
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
WO1988004777A1 (fr) 1986-12-15 1988-06-30 Ultra Diagnostics Corporation Reactifs de phtalocyanine monomeres
US4876190A (en) 1987-10-21 1989-10-24 Becton Dickinson & Company Peridinin-chlorophyll complex as fluorescent label
FR2624862B1 (fr) 1987-12-18 1990-06-08 Oris Ind Cryptates de terres rares, procedes d'obtention, intermediaires de synthese et application a titre de marqueurs fluorescents
CN101308144A (zh) * 2007-05-16 2008-11-19 首都医科大学宣武医院 检测受试者体液内疾病相关蛋白聚合能力的方法
FR2934684B1 (fr) * 2008-07-31 2012-11-16 Cis Bio Int Methode de detection de l'internalisation de proteines membranaires.
EA201100297A1 (ru) 2008-08-04 2011-10-31 Новартис Аг Биотесты на белок polyq
GB0915986D0 (en) * 2009-09-14 2009-10-28 Sec Dep For Environment Food A Detection method
CN110655573B (zh) * 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
US20130183696A1 (en) * 2010-09-15 2013-07-18 Constance Neely Wilson Methods of use and kit for measurement of lipopolysaccharide with a time resolved fluorescence based assay
AU2011336895A1 (en) 2010-11-24 2013-06-06 Elan Pharmaceuticals, Inc. Phagocytic activity as a marker of synucleinopathic disease
ES2841739T3 (es) 2013-12-03 2021-07-09 Cezanne S A S Método para la determinación selectiva del factor de crecimiento placental 2
CN106062559B (zh) * 2014-06-27 2018-12-14 北京新源长青生物科技有限公司 用于富集cns来源的外泌体的方法
EP3191599B1 (fr) 2014-09-11 2023-08-02 Board Of Regents Of the University Of Texas System Détection de protéines mal-repliées
JP6989927B2 (ja) * 2015-08-25 2022-02-03 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ－シヌクレインを検出するための方法

Also Published As

Publication number Publication date
ES2898929T3 (es) 2022-03-09
WO2019121952A1 (fr) 2019-06-27
EP3729088A1 (fr) 2020-10-28
US20200309796A1 (en) 2020-10-01
JP2024096748A (ja) 2024-07-17
JP2021508044A (ja) 2021-02-25
JP7498663B2 (ja) 2024-06-12
CN120195406A (zh) 2025-06-24
EP3729088B1 (fr) 2021-10-20
CN111630382A (zh) 2020-09-04

Similar Documents

Publication Publication Date Title
EP3664796A4 (fr) Composition de cannabinoïde enrichie en terpène et procédé de traitement
EP3649962A4 (fr) Dispositif médical et procédé de traitement
EP3681479A4 (fr) Méthode d'administration et de traitement
EP3341001A4 (fr) Composition et procédé pour le traitement et la prophylaxie d'infection et d'inflammation intestinale
EP3639967A4 (fr) Appareil de traitement et procédé de traitement
EP3328277A4 (fr) Systèmes, dispositifs et procédé permettant le traitement de l'arthrose
EP3817733A4 (fr) Composition et procédé de traitement de la douleur
EP3391873A4 (fr) Procédé et ensemble de traitement capillaire
EP3439231A4 (fr) Noeud privé, procédé de traitement pour noeud privé et programme associé
EP3452166A4 (fr) Stimulation intranasale pour le traitement de la maladie de la glande de meibomius et de la blépharite
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3423100A4 (fr) Compositions destinées à traiter l'inflammation et méthodes de traitement associées
EP3327214A4 (fr) Structure d'ossature et son procédé de construction
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
EP3600374C0 (fr) Traitement d'une infection respiratoire
EP3318267A4 (fr) Agent thérapeutique et procédé de traitement de maladie de hunter
EP3191182A4 (fr) Appareil et procédé pour fournir un traitement thérapeutique de l'hyperthermie
EP3876583A4 (fr) Procédé de traitement et terminal
EP3554310A4 (fr) Composition de traitement de la peau emballée et procédé
EP3915402A4 (fr) Appareil de traitement, procédé de traitement et corps pulvérulent
IL261476B (en) A system and method for in-line treatment of thread for use with a thread consumption device
EP3316874A4 (fr) Compositions topiques et injectables de résiquimod pour le traitement d'affections cutanées néoplasiques
EP3546449A4 (fr) Dérivé de pipéridine -2,6-dicétone et traitement de la maladie de crohn
EP3995588A4 (fr) Procédé et application de création de banque
EP3352752A4 (fr) Détection et traitement d'un déficit en hormone de croissance